AIM ImmunoTech Inc. entered into a note purchase agreement with new lender Streeterville Capital, LLC, and announced that it has issued non-convertible unsecured promissory note with an original principal amount of $3,301,250 on February 16, 2024. The note carries an original issuance discount of $781,250 and the company agreed to pay $20,000 to the Investor to cover the Investor?s legal and administrative transaction costs, each of which were included in the original principal amount and deducted from the proceeds of the note received by the company which resulted in a purchase price received by the company of $2,500,000. The note bears interest at 10% per annum compounded daily.

The maturity date of the note is 24 months from the date of its issuance. Beginning on the date that is six months after the Purchase Price Date, Investor shall have the right, exercisable at any time in its sole and absolute discretion, to redeem any amount of the Note up to $250,000 per calendar month by providing written notice to the company; provided, however, that if the Investor does not exercise any Monthly Redemption Amount in its corresponding month then such Monthly Redemption Amount shall be available for the Investor to redeem in any future month in addition to such future month?s Redemption Amount. Upon receipt of any Monthly Redemption Notice, the company shall pay the applicable Monthly Redemption Amount in cash to the Investor within three business days of the company?s receipt of such Monthly Redemption Notice.

The company may prepay any or all of the outstanding balance under the Note prior to the Maturity Date, provided that if such prepayment covers less than the entire principal, fees and interest of the Note, the Company will remain subject to the remaining obligations under the Note. The minimum investment accepted from any outside investor is $2,500,000. The company has issued securities pursuant to exemption provided under Regulation D.